Gastrointestinal Cancer News

Eradication and recurrence rates of dysplasia or neoplasia are similar in patients with Barrett’s esophagus and high-grade dysplasia or intramucosal carcinoma who receive endoscopic eradication therapy, according to recent study data.

Molecular testing of all tumors for RAS mutations in patients with metastatic colorectal cancer should be standard practice to help guide decisions about use of anti-epidermal growth factor receptor therapy, according to a reassessment of results from the phase 3 CRYSTAL study.

Patients with advanced pancreatic cancer who received palliative care underwent less aggressive end-of-life treatment, required fewer hospital admissions and survived longer than those who did not receive palliative care, according to study results.

Patients with stage I to stage III colon adenocarcinoma who underwent complete mesocolic excision demonstrated longer DFS than those who underwent standard rectal surgery, according to results of a retrospective study conducted in Denmark.

PancraGen, an integrated molecular pathology test that combines molecular analysis with clinical test results to assess the malignant potential of pancreatic cysts, provided more accurate results compared with management recommended by current guidelines in a recent trial.

World Cancer Day is today, February 4. Healio.com/Hepatology compiled a list of the latest studies focusing on hepatocellular carcinoma research and advancements. 

A less-intensive first-line treatment regimen for patients with metastatic pancreatic cancer may decrease toxicity and reduce costs while maintaining efficacy, according to data from a single-institution study presented at the Gastrointestinal Cancers Symposium.

Patients with RAS wild-type metastatic colorectal cancer treated with panitumumab plus modified FOLFOX6 chemotherapy experienced faster and more durable responses than those treated with bevacizumab plus FOLFOX6, according to phase 2 study results presented at the Gastrointestinal Cancers Symposium.

Researchers have identified subtypes of stage III colon cancer based on molecular markers associated with differences in clinical and pathological features as well as disease-free survival.

Patients with locally advanced, unresectable pancreatic adenocarcinoma experienced favorable survival when they received neoadjuvant gemcitabine, docetaxel and capecitabine, according to study results.